density of synapses and larger extracellular space in the developing brain may reduce the concentration of potentially excitotoxic glutamate. Furthermore, the fact that GABA provides a significant component of the excitatory driving force will reduce the pathological consequences of seizures because of the smaller driving force and the shunting effects of GABA.
However, it is becoming clear that seizures do not necessarily need to cause cell death to result in adverse outcomes. While prolonged seizures may cause less cell loss in young animals, there are nonetheless clear indications that they may have other potentially deleterious effects. Following kindling, immature rats, like adult rats, have a permanent reduction in seizure threshold. Recurrent seizures during the neonatal period also result in clear deficits in learning and memory when the animals are studied as adults, despite the lack of clear cell loss (Neill et al., 1996) . This may be due to the fact that seizures may perturb a wide range of phenomena that are activity dependent, including cell division and migration, sequential expression of receptors, and formation and probably stabilization of synapses. Paroxysmal discharges may facilitate an early expression of glutamatergic receptors and alter the formation of functional entities as "cells that fire together wire together" (Goodman and Shatz, 1993).
We have found that recurrent flurothyl-induced sei- as the ethical concerns about drug testing in infants.
Based on the sequential developmental pattern of pre-and postsynaptic neurotransmitter receptor development described previously, drugs that are likely to be beneficial in neonatal seizures would be those that have their effect on the NMDA receptor, presynaptic GABA B receptors, or voltage-gated channels. Unfortunately, drugs that block the NMDA receptor, such as topiramate, have been tested sparingly in neonates because of the concern that treatment with excitatory amino acid antagonists may interfere with learning, memory, and brain plasticity. No antiepileptic drugs are currently available that are specific agonists of the GABA B receptor. Thus, while there has been tremendous progress made in the pharmacological treatment of seizures in older children and adults, the current methods to treat neonatal seizures have not changed in the last 50 years. While a better understanding of the mechanisms responsible for seizure-induced damage is critical, an even greater challenge is to develop drugs that inhibit neonatal seizures without otherwise interfering with brain development or physiology.
